Jump to content
Paul Edwards

Denosumab therapy and risk for severe hypocalcemia

Recommended Posts

Paul Edwards

Denosumab (brand name Xgeva)  is associated with a rare but well-known risk for severe hypocalcemia (very low calcium in the blood stream).


The "New" Prostate Cancer InfoLink has an article about this risk which includes a very sensible warning:


"If your doctor advises you that you would be appropriately treated with denosumab for prevention of skeletal-related events associated with advanced forms of prostate cancer (particularly in men with metastatic disease on long-term androgen deprivation therapy), you need to be sure that your serum calcium and vitamin D levels are monitored prior to initiation of therapy."

Share this post

Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...